Cargando…
Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review
Osteoporosis and its associated fracture risk has become one of the major health burdens in our aging population. Currently, bisphosphonate, one of the most popular antiresorptive drugs, is used widely to treat osteoporosis but so far still no consensus has been reached for its application in treatm...
Autores principales: | Suen, Pui Kit, Qin, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Speaking Orthopaedic Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987014/ https://www.ncbi.nlm.nih.gov/pubmed/30035061 http://dx.doi.org/10.1016/j.jot.2015.08.004 |
Ejemplares similares
-
Serum sclerostin levels in osteoporotic fracture patients
por: Gorter, Erwin A., et al.
Publicado: (2022) -
Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016) -
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
por: Shah, Arti D, et al.
Publicado: (2015) -
Osteoporosis and Osteoporotic Fractures in Gastrointestinal Disease
por: Oh, Hyun Jin, et al.
Publicado: (2018) -
Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis
por: Aditya, Suruchi, et al.
Publicado: (2021)